title: Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: what have we learnt?
abstract: Cushing's syndrome (CS) has a considerable negative impact on patient health-related quality of life (HRQoL). Two disease-specific instruments (the CushingQoL and the Tuebingen CD-25 questionnaire) are now available to assess the impact of the disease and its treatment on HRQoL. The purpose of this review was to summarize the characteristics of the studies which have used these two instruments to date and summarize their findings regarding (a) the determinants of disease-specific HRQoL in patients with CS and (b) the impact of treatment for CS on disease-specific HRQoL. A total of 7 studies were identified, 5 with the CushingQoL and 2 with the Tuebingen CD-25. Most were observational studies, though the CushingQoL had been used in one randomized clinical trial. In terms of clinical factors, there was some evidence for an association between UFC levels and disease-specific HRQoL, though the presence and strength of the association varied between studies. There was also some evidence that a more recent diagnosis of CS could lead to poorer HRQoL, and that length of time with adrenal insufficiency may also affect HRQoL. There was no evidence for an impact on disease-specific HRQoL of etiology or of the clinical signs and symptoms associated with CS, such as bruising, rubor, and fat deposits. One factor which did have a significant negative effect on HRQoL was the presence of depression. No clear picture emerged as to the effect of demographic variables such as age and gender on HRQoL scores, though there was some evidence for poorer HRQoL in female patients. As regards treatment, the two interventions studied to date (transsphenoidal surgery and pasireotide) both showed significant gains in HRQoL, with moderate to large effect sizes. This type of review is useful in summarizing knowledge to date and suggesting future research directions.
authors.affiliation: Health Economics and Outcomes Research, IMS Health, C/Dr. Ferran 25-27, 2º, 08034, Barcelona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: Badia
authors.forename: E
authors.initials: E
authors.lastname: Valassi
authors.forename: M
authors.initials: M
authors.lastname: Roset
authors.forename: S M
authors.initials: SM
authors.lastname: Webb
mesh_terms: D003480:Cushing Syndrome / Q000523:psychology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D019635:Neurosurgical Procedures; D047748:Pituitary ACTH Hypersecretion / Q000601:surgery; D011594:Psychometrics; D011788:Quality of Life / Q000523:psychology*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D013004:Somatostatin; C517782:pasireotide
references.citation: Psychol Med. 1998 May;28(3):551-8
references.pmid: 9626712
references.citation: Clin Endocrinol (Oxf). 2012 Jun;76(6):851-60
references.pmid: 21801193
references.citation: Lupus. 2011 Oct;20(12):1285-92
references.pmid: 21813589
references.citation: Qual Life Res. 1998 May;7(4):311-22
references.pmid: 9610215
references.citation: Int J Obes (Lond). 2011 Aug;35(8):1087-94
references.pmid: 21042326
references.citation: Eur J Endocrinol. 2012 Sep;167(3):337-42
references.pmid: 22677433
references.citation: Clin Endocrinol (Oxf). 2012 Jun;76(6):861-7
references.pmid: 22066792
references.citation: Ann Surg. 2007 May;245(5):790-4
references.pmid: 17457173
references.citation: Surgery. 2002 Dec;132(6):1064-8; discussion 1068-9
references.pmid: 12490856
references.citation: Diabetes Care. 1997 Apr;20(4):562-7
references.pmid: 9096981
references.citation: Diabetes Care. 2004 May;27(5):1066-70
references.pmid: 15111522
references.citation: J Clin Endocrinol Metab. 2005 Jun;90(6):3279-86
references.pmid: 15741267
references.citation: N Engl J Med. 2012 Mar 8;366(10):914-24
references.pmid: 22397653
references.citation: Eur J Endocrinol. 2011 Oct;165(4):527-35
references.pmid: 21798958
references.citation: Eur J Endocrinol. 2011 Sep;165(3):383-92
references.pmid: 21715416
references.citation: J Clin Endocrinol Metab. 2006 Feb;91(2):447-53
references.pmid: 16278266
references.citation: Neuroendocrinology. 2010;92 Suppl 1:1-5
references.pmid: 20829610
references.citation: Eur J Endocrinol. 2008 May;158(5):623-30
references.pmid: 18426820
references.citation: J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602
references.pmid: 14671138
references.citation: Clin Endocrinol (Oxf). 2008 Nov;69(5):775-84
references.pmid: 18462264
references.citation: Endocrinol Metab Clin North Am. 1994 Sep;23(3):607-17
references.pmid: 7805657
references.citation: Health Qual Life Outcomes. 2004 May 05;2:21
references.pmid: 15128455
references.citation: Rev Endocr Metab Disord. 2010 Jun;11(2):95-104
references.pmid: 19960264